ArticleEvidence-based medicine2017
Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
Denise Campbell-SchererPubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this paperpooled itcites it